Source: foxnews.com
Summary
A new study suggests that the anti-seizure medication levetiracetam, first approved by the FDA in 1999, may have potential in preventing Alzheimer’s disease. Researchers at Northwestern University found that the medication prevented the formation of toxic amyloid beta peptides in both animal models and cultured human neurons. The study’s findings were published in Science Translational Medicine. The researchers also analyzed previous human clinical data and found that Alzheimer’s patients taking the medication had a “significant delay” in cognitive decline.
Our Reading
The advice sounds familiar. Levetiracetam, an anti-seizure medication, is now being explored as a potential means of Alzheimer’s prevention. This is not the first time a medication has been repurposed for a different condition. The study’s findings are promising, but it’s essential to note that the medication’s effectiveness in preventing Alzheimer’s is still in its early stages. The researchers aim to conduct further testing, including human trials, to confirm their findings. Meanwhile, the medication’s common side effects and potential risks must be considered.
The repetition of “new” treatments and the cautious language used by researchers (“may have potential,” “suggests”) is a familiar pattern in health guidance. The rebranding of existing medications for new conditions is also a common occurrence. As with any new development, it’s crucial to approach the findings with a critical and nuanced perspective, acknowledging both the potential benefits and the limitations of the research.
Author: Evan Null
